Open Source Securities released a research report on April 20 stating that it gave Jichuan Pharmaceutical (600566.SH) a purchase rating. The main reasons for the rating include: 1) the rotation and handover of growth drivers, and pediatrics has become the mainstay; 2) optimizing the product structure, steady growth in basic markets, and accelerating the release of advantageous individual products; 3) increasing the introduction and R&D of new products, deepening sales advantages and enabling sustainable development. (Mainichi Keizai Shimbun)
开源证券4月20日发布研报称，给予济川药业（600566.SH）买入评级。评级理由主要包括：1）增长动力轮换交接，儿科已成中流砥柱；2）产品结构优化，基本盘稳定增长、优势单品加速放量；3）加大新品引进及研发力度，深化销售优势赋能可持续发展。（每日经济新闻）
Open Source Securities released a research report on April 20 stating that it gave Jichuan Pharmaceutical (600566.SH) a purchase rating. The main reasons for the rating include: 1) the rotation and handover of growth drivers, and pediatrics has become the
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.